Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia

被引:23
|
作者
Rissiek, Anne [1 ]
Schulze, Christian [2 ]
Bacher, Ulrike [3 ]
Schieferdecker, Aneta [4 ]
Thiele, Benjamin [4 ]
Jacholkowski, Anita [4 ]
Flammiger, Anna [4 ]
Horn, Christiane [4 ]
Haag, Friedrich [1 ]
Tiegs, Gisa [5 ]
Zirlik, Katja [6 ]
Trepel, Martin [4 ]
Tolosa, Eva [1 ]
Binder, Mascha [4 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Inst Immunol, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol Hamburg ZMNH, D-20246 Hamburg, Germany
[3] MLL, Munich, Germany
[4] Univ Canc Ctr Hamburg, BMT Sect Pneumol, Dept Hematol & Oncol, Hubertus Wald Tumorzentrum, Hamburg, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Inst Expt Immunol & Hepatol, D-20246 Hamburg, Germany
[6] Univ Med Ctr Freiburg, Dept Hematol & Oncol, Freiburg, Germany
关键词
CLL; MBL; regulatory T-cells; multidimensional analysis; T-cell profiling; B-CELLS; CYTOKINE PRODUCTION; UP-REGULATION; LENALIDOMIDE; EXPRESSION; CD80; MBL; COSTIMULATION; DYSFUNCTION; ACTIVATION;
D O I
10.1002/ijc.28884
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antitumor immunity in chronic lymphocytic leukemia (CLL) is hampered by highly dysfunctional T-cells. Although certain T-cell subsets have been reported to be of prognostic significance in this disease, their interplay is complex and it remains incompletely understood which of these subsets significantly drive CLL progression. Here, we determined immunological profiles of 24 circulating T-cell subsets from 79 untreated individuals by multiparametric flow cytometry. This screening cohort included healthy donors, patients with monoclonal B-cell lymphocytosis (MBL), Rai 0 CLL and advanced CLL. We applied multidimensional scaling analysis as rigorous and unbiased statistical tool to globally assess the composition of the circulating T-cell environment and to generate T-cell scores reflecting its integrity. These scores allowed clear distinction between advanced CLL and healthy controls, whereas both MBL and Rai 0 CLL showed intermediate scores mirroring the biological continuum of CLL and its precursor stages. T-cell stimulation and suppression assays as well as longitudinal T-cell profiling showed an increasingly suppressive regulatory function initiating at the MBL stage. Effector function was impaired only after transition to CLL and partially recovered after chemoimmunotherapy. In an independent validation cohort of 52 untreated CLL cases, aberrant T-cell profiles were significantly associated with shorter time to treatment independently of other prognostic parameters. Random forest modeling predicted regulatory T-cell, gamma/delta and NKT-cells, as well as exhaustion of the CD8+ subset as potential drivers of progression. Our data illustrate a pathological T-cell environment in MBL that evolves toward a more and more suppressive and prognostically relevant profile across the disease stages.
引用
收藏
页码:2370 / 2379
页数:10
相关论文
共 50 条
  • [31] Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias
    Lad, Deepesh P.
    Varma, Subhash
    Varma, Neelam
    Sachdeva, Man Updesh Singh
    Bose, Parveen
    Malhotra, Pankaj
    LEUKEMIA & LYMPHOMA, 2013, 54 (05) : 1012 - 1019
  • [32] THE INFLUENCE OF T-CELLS FROM PATIENTS WITH B-CHRONIC LYMPHOCYTIC-LEUKEMIA ON INVITRO IGM SYNTHESIS
    WHELAN, CA
    MCCANN, SR
    BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) : 325 - 325
  • [33] Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia
    Mpakou, Vassiliki E.
    Ioannidou, Heleni-Dikaia
    Konsta, Eugene
    Vikentiou, Myrofora
    Spathis, Aris
    Kontsioti, Frieda
    Kontos, Christos K.
    Velentzas, Athanassios D.
    Papageorgiou, Sotiris
    Vasilatou, Diamantina
    Gkontopoulos, Konstantinos
    Glezou, Irene
    Stavroulaki, Georgia
    Mpazani, Efthimia
    Kokkori, Stella
    Kyriakou, Elias
    Karakitsos, Petros
    Dimitriadis, George
    Pappa, Vasiliki
    LEUKEMIA RESEARCH, 2017, 60 : 74 - 81
  • [34] Proteomic analysis of chronic lymphocytic leukemia cells identifies vimentin as a novel prognostic factor for aggressive disease.
    Nowakowski, GS
    Lee, YK
    Bone, ND
    Morice, WG
    Barnidge, D
    Jelinek, DF
    Tschumper, R
    Shanafelt, TD
    Zent, CS
    Rassenti, LZ
    Kipps, TJ
    Kay, NE
    BLOOD, 2005, 106 (11) : 209A - 209A
  • [35] Significantly shorter telomeres in T-cells of ZAP-70*/CD38+ patients with chronic lymphocytic leukemia (CLL):: An important role of T-cells in this subgroup of CLL?
    Roeth, Alexander
    de Beer, Dirk
    Nueckel, Holger
    Sellmann, Ludger
    Duehrsen, Ulrich
    Duerig, Jan
    Baerlocher, Gabriela M.
    BLOOD, 2007, 110 (11) : 340A - 340A
  • [36] An update on immunotherapies including chimeric antigen receptor T-cells therapy and stem cell transplantation in chronic lymphocytic leukemia
    Schachter, Levanto G.
    Mato, Anthony R.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (01) : 68 - 77
  • [37] FLUDARABINE MONOPHOSPHATE (FAMP) INDUCED APOPTOSIS OF LEUKEMIC-B AND NORMAL T-CELLS IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    CONSOLI, U
    KLEINE, HD
    BROWN, WD
    RAIMONDO, FD
    ANDREEFF, M
    BLOOD, 1994, 84 (10) : A458 - A458
  • [38] THE INCIDENCE OF T-CELLS WITH DIFFERENT MEMBRANE-CHARACTERISTICS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA IN RELATION TO DISEASE PROGRESSION
    BENKOVIC, B
    JAKSIC, B
    VITALE, B
    PERIODICUM BIOLOGORUM, 1983, 85 : 213 - 214
  • [39] PHYTOHEMAGGLUTININ OR POKEWEED MITOGEN INDUCTION OF INVITRO COLONY FORMATION BY T-CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA
    PISTOIA, V
    NOCERA, A
    GHIO, R
    MINALE, P
    FERRARINI, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1982, 68 (02) : 233 - 237
  • [40] Generation and preclinical evaluation of a novel ROR1-specific CAR T-cells against chronic lymphocytic leukemia
    Hasan, Md Kamrul
    Oh, Christopher
    Girgis, Christina
    Widhopf, George
    Prussak, Charles
    Kipps, Thomas
    LEUKEMIA & LYMPHOMA, 2023, 64 : S195 - S195